Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study
Catherine B. Johannes,Ryan Ziemiecki,Manel Pladevall-Vila,Natalie Ebert,Csaba P. Kovesdy,Reimar W. Thomsen,Brenda N. Baak,Aníbal García-Sempere,Hiroshi Kanegae,Craig I. Coleman,Michael Walsh,Ina Trolle Andersen,Clara Rodríguez Bernal,Celia Robles Cabaniñas,Christian Fynbo Christiansen,Alfredo E. Farjat,Alain Gay,Patrick Gee,Ron M. C. Herings,Isabel Hurtado,Naoki Kashihara,Frederik Pagh Bredahl Kristensen,Fangfang Liu,Suguru Okami,Jetty A. Overbeek,Fernie J. A. Penning-van Beest,Satoshi Yamashita,Yuichiro Yano,J. Bradley Layton,David Vizcaya,Nikolaus G. Oberprieler
DOI: https://doi.org/10.1007/s13300-024-01671-x
2024-12-18
Diabetes Therapy
Abstract:The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148), we described and compared cohorts of adult patients with CKD and T2D initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) before the launch of finerenone in Europe, Japan, and the United States (US).
endocrinology & metabolism